UCB (OTCMKTS:UCBJF) Hits New 12-Month High - Here's Why

Key Points

• UCB SA's shares reached a new 52-week high of $306.39 during mid-day trading, closing slightly higher at $306.39 with a volume of only 27 shares.
• Analysts have reaffirmed their positive views on UCB, with Morgan Stanley and Deutsche Bank both giving "overweight" and "buy" ratings respectively, leading to a consensus "Buy" rating for the stock.
• The company, a biopharmaceutical firm, specializes in developing treatments for conditions such as neurology and immunology diseases, boasting products like Cimzia and Vimpat.

Shares of UCB SA (OTCMKTS:UCBJF - Get Free Report) hit a new 52-week high during mid-day trading on Monday . The company traded as high as $306.39 and last traded at $306.39, with a volume of 27 shares. The stock had previously closed at $305.09.

Analysts Set New Price Targets

UCBJF has been the subject of several analyst reports. Morgan Stanley reissued an "overweight" rating on shares of UCB in a report on Monday, September 8th. Deutsche Bank Aktiengesellschaft reissued a "buy" rating on shares of UCB in a report on Monday, October 6th. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy".

UCB Stock Performance

The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The stock has a fifty day simple moving average of $247.61 and a two-hundred day simple moving average of $203.86.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.